Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Lung Cancer ; (12): 487-492, 2022.
Artigo em Chinês | WPRIM | ID: wpr-939736

RESUMO

The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to provide references for the application of MIDD to guide the clinical research of antitumor drugs.
.


Assuntos
Humanos , Antineoplásicos/uso terapêutico , Desenvolvimento de Medicamentos , Neoplasias Pulmonares
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA